Mankind Pharma Ltd Share Price

Q: What is the share price of Mankind Pharma Ltd today?

Mankind Pharma Ltd share price as on 22 Jan 2025 is ₹2520.05

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

NSE: MANKIND Large Cap ISIN: INE634S01028

As on 22 January 2025 at 15:04 IST

₹2,520.05

-43.50

(-1.70%)

Sell Buy

About Mankind Pharma Ltd

Mankind Pharma Ltd is a prominent pharmaceutical company in India, engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations. It operates within the pharmaceutical sector. The company was incorporated in the year 1991 and began its operations in 1995. Over the years, it has grown to become one of the top pharmaceutical companies in India, known for its commitment to quality and affordability. The headquarters of Mankind Pharma is located in New Delhi, India. Mankind Pharma's main products include a wide range of pharmaceuticals and consumer healthcare products. Read More...

Over 1 Month

-14.50%

Over 6 Months

21.59%

Over 1 Year

19.63%

Over 3 Years

Mankind Pharma Ltd Summary

Close ₹ 2,520.05

Open ₹ 2,573.55

High ₹ 2,585.90

Low ₹ 2,488

Volume 2,04,487

Net Turnover (in ₹) ₹ 93,80,30,578.15

52Wk High ₹ 3,054.80

52Wk Low ₹ 1,901.05

52Wk High / Low

1,901.05

3,054.80

Mankind Pharma Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 1,05,763.59

EPS (TTM) 48.58

Book Value (BV) 334.18

Div. Yield -

P/E (TTM) 50.62

Price/Book Value 7.67

Delivery % 44.02 %

Face Value 1

Key Ratios

PE Ratio 50.47

PB Ratio 9.56

EV to Sales 9.85

PEG Ratio 1.10

ROA 18.69

ROE 20.95

Debt-Equity -

Net Profit Margin 19.68

Operating Profit Margin 27.98

Mankind Pharma Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	10,615.63	8,878	7,977.58	6,385.38	5,975.65
Total Expenses	8,231.49	7,219.18	6,017.43	4,705.45	4,549.45
Profit Before Tax	2,399.36	1,671.24	1,974.60	1,691.61	1,437.73
Profit After Tax	1,941.77	1,309.68	1,452.96	1,293.03	1,056.15
Operating Profit after Depreciation	2,417.68	1,703.28	2,018.76	1,700.08	1,448.17

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	4,614.65	4,302.24	3,614.37	1,659.28	1,597.73
Total Non Current Assets	5,395.03	5,387.58	4,740.92	2,465.99	2,251.07
Total Current Assets	6,568.23	4,327.87	4,406.82	3,906.64	2,822.22
TOTAL ASSETS	11,963.25	9,715.45	9,147.74	6,372.63	5,073.28
Total Shareholder's Fund	9,363.09	7,435.22	6,155.23	4,722	3,485.31

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	2,152.45	1,813.30	919.78	1,137.24	1,069.71
Net Cash used in Investing Activities	-2,080.52	-1,051.81	-1,368.67	-1,221.84	-435.55
Net Cash used in Financing Activities	5.27	-739.73	604.62	-7.81	-530.74

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	9,531.45	8,289.94	7,690.04	5,677.68	4,888.26
Total Expenses	7,271.88	6,727.10	5,818.60	4,237.47	3,623.34
Profit Before Tax	2,259.57	1,562.84	1,871.44	1,440.21	1,264.92
Profit After Tax	1,823.41	1,248.26	1,389.42	1,084.37	958.23
Operating Profit after Depreciation	2,274.14	1,590.58	1,918.56	1,448.19	1,275.54

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	3,473.77	3,193.85	2,952.58	982.01	942.95
Total Non Current Assets	5,927.30	5,854.21	5,122.99	2,790.35	2,582.50
Total Current Assets	5,490.41	3,516.91	3,815.71	3,089.98	1,948.60
TOTAL ASSETS	11,417.71	9,371.12	8,938.70	5,880.33	4,531.11
Total Shareholder's Fund	9,623.81	7,783.91	6,540.45	4,734.27	3,651.45

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	1,982.97	1,798.99	821.44	983.38	959.61
Net Cash used in Investing Activities	-1,919.22	-1,040.61	-1,360.27	-1,127.16	-395.68
Net Cash used in Financing Activities	-8.68	-710.41	578.63	88.87	-558.91

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	3,076.51	2,893.42	2,441.10	2,606.96	2,708.10
Total Expenses	2,226.47	2,211.66	1,850	2,000.45	2,025.45
Profit Before Tax	849.32	667.62	571.57	562.32	640.99
Profit After Tax	658.88	543.07	476.59	459.81	511.18
Operating Profit after Depreciation	962.04	786.27	685.64	681.24	746.10

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	2,529.74	2,403.26	1,996.55	2,358.57	2,260.47
Total Expenses	1,777.71	1,831.06	1,481.38	1,755.46	1,662.33
Profit Before Tax	802.44	606.61	536.32	576.35	601.02
Profit After Tax	634.43	513.49	454.17	487.07	472.88
Operating Profit after Depreciation	889.78	696.27	622.60	670.34	682.34

Mankind Pharma Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 2,514.20

S2 2,464.85

S3 2,377.70

Pivot 2,601.35

R1 2,650.70

R2 2,737.85

R3 2,787.20

Moving Average

20 SMA 2,784.04

50 SMA 2,698.80

100 SMA 2,634.84

200 SMA 2,415.77

Mankind Pharma Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

No available data

Mankind Pharma Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Mankind Pharma Ltd	₹2,563.35	₹1,05,755.34
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73

Mankind Pharma Ltd News

Mankind Pharma to table results

On 23 January 2025

13 Jan 2025, 05:30 pm

Mankind Pharma allots 1.19 cr equity shares under QIP issue

20 Dec 2024, 02:17 pm

Mankind Pharma raises nearly Rs 3,000 crore from eligible institutional buyers via QIP issue

Mankind Pharma said that its board has approved the closure of the issue for the qualified institutions placement of equity shares of the company on Thursday, 19 December 2024.

20 Dec 2024, 11:52 am

Mankind Pharma edges higher after board approves opening of Rs 3,000 crore QIP issue

Mankind Pharma added 1.17% to Rs 2722.15 after the company informed that its board has approved the opening of issue of qualified institutional placement (QIP) of equity shares with the floor price of Rs 2,616.55 per equity share.

17 Dec 2024, 10:07 am

Mankind Pharma Ltd rises for third consecutive session

Mankind Pharma Ltd is quoting at Rs 2609.95, up 1.9% on the day as on 12:49 IST on the NSE. The stock is up 35.66% in last one year as compared to a 16.91% spurt in NIFTY and a 38.53% spurt in the Nifty Pharma index.

02 Dec 2024, 01:05 pm

Mankind Pharma Ltd Stock Analysis

Annual revenue for Mankind Pharma Ltd increased by 14.98% to ₹9,531.45 crore in FY 2024 from ₹8,289.94 crore in FY 2023.
Annual Net Profit for Mankind Pharma Ltd increased by 46.08% to ₹1,823.41 crore in FY 2024 from ₹1,248.26 crore in FY 2023.
Promoter Shareholding in Mankind Pharma Ltd decreased by 2.89% in the most recent quarter, from 74.87% in September 2024 to 72.71% in December 2024.
Mankind Pharma Ltd delivered a 1-year return of 19.63% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Mankind Pharma Ltd share price moved down by 1.70% from its previous close of INR ₹2,563.55. The latest Mankind Pharma Ltd share price is INR ₹2,520.05.
Mankind Pharma Ltd share price today has been at a low of 2,488 and a high of 2,585.90. Over the past 52 weeks, the Mankind Pharma Ltd share price has seen a low of 1,901.05 and a high of 3,054.80.

About Mankind Pharma Ltd

Mankind Pharma Ltd is a prominent pharmaceutical company in India. It is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations. The company operates in various therapeutic areas, including antibiotics and erectile dysfunction medications. Additionally, Mankind Pharma has a strong presence in the consumer healthcare segment. Its products include condoms, pregnancy detection kits, and emergency contraceptives.

Mankind Pharma falls under the pharmaceutical sector. The company was incorporated in 1991 and began its operations in 1995. Over the years, it has grown to become one of the top pharmaceutical companies in India, known for its commitment to quality and affordability.

The headquarters of Mankind Pharma is located in Okhla Phase III, New Delhi, India. The promoters of the company include Ramesh Juneja Family Trust, with a 20.80% stake. A team of managerial promoters manage the operations of the company. They are

Rajeev Juneja
Sheetal Arora
Satish Kumar Sharma
Vivek Kalra

Mankind Pharma's main products include a wide range of pharmaceuticals and consumer healthcare products. Some of its well-known brands include Manforce (condoms), Prega News (pregnancy detection kits), and Unwanted-72 (emergency contraceptive pills). It also offers prescription medications such as Telmikind, Moxikind-CV, and Nurokind. The company also manufactures over-the-counter products.

Mankind Pharma is a leading player in the pharmaceutical industry. Still, it is not the largest in terms of market share or capitalization. However, it is recognized for its strong market presence and innovative products. The company has a market capitalization of approximately ₹1.082 trillion. This makes it one of the most valuable pharmaceutical companies in India. The registered office of Mankind Pharma Ltd is in Okhla Industrial Estate, New Delhi. Meanwhile the office of the registrars is in Hyderabad, Telangana.

The vision of Mankind Pharma Limited

Mankind Pharma Ltd envisions a future where high-quality healthcare is accessible and affordable to all. The company's vision is to become a global pharmaceutical leader. It aims to be admired for its commitment to the affordability and accessibility of its products.

The company aims to provide cost-effective pharmaceutical products that improve the lives of patients. Mankind Pharma focuses on innovation to develop superior-quality medications. This commitment to innovation allows the company to meet the growing needs of society. It also helps provide solutions for various health challenges.

Mankind Pharma's vision includes a strong emphasis on quality. The company believes that maintaining high standards of quality is essential for building trust with its customers. This focus on quality is reflected in every aspect of the company's operations, from research and development to manufacturing and distribution. Mankind Pharma strives to deliver products that meet the highest standards of safety and efficacy.

Accessibility is another key component of Mankind Pharma's vision. The company aims to make its products available across different geographic regions. This includes expanding its presence in rural and underserved areas where access to healthcare is often limited. Mankind Pharma believes that making its products widely available can help bridge the gap in healthcare access. This, in turn, can improve the overall health of communities.

The company's vision also includes a commitment to sustainability. Mankind Pharma is dedicated to operating in an environmentally responsible manner. This includes implementing sustainable business practices and supporting initiatives that promote environmental conservation.

Mankind Pharma's vision is supported by a strong corporate culture that values integrity and accountability. The company believes that adhering to these principles is essential for building trust with its customers and stakeholders. This trust is crucial for achieving the company's long-term goals and sustaining its growth.

The company also places a strong emphasis on customer-centricity. Mankind Pharma strives to understand the needs of its customers and provide personalized solutions. This customer-centric approach enables the company to build strong relationships with its customers. It also helps deliver products that meet their specific needs.

Mankind Pharma's vision includes a focus on continuous improvement. The company is committed to constantly enhancing its products and services. This includes investing in research and development to develop new and innovative solutions.

The company's vision is also aligned with its mission to improve the quality of life for patients. Mankind Pharma aims to provide medications that help people lead healthier lives. This includes developing treatments for various acute and chronic conditions. The company believes that improving the health of individuals can have a positive impact on society as a whole.

Mankind Pharma's vision extends beyond its products and services. The company is actively involved in corporate social responsibility (CSR) initiatives. These initiatives focus on areas such as health, education, and community development. Mankind Pharma believes that giving back to society is an important part of its vision and mission.

The company's vision is also reflected in its strategic priorities. These include expanding its global presence and improving its operational efficiency. Mankind Pharma aims to achieve these goals by leveraging its strengths and capitalizing on opportunities in the market.

A dedicated team of professionals supports Mankind Pharma's vision. The company's employees are committed to achieving its vision and mission. Mankind Pharma believes that investing in its people is essential for driving innovation and achieving its strategic objectives.